Matinas BioPharma | Investor Presentation Deck | 29 slides · page 21 of 29
The chart shows dose-response curves where LNC formulations consistently outperform Taxol.
Deck · key_takeaways · analyze_data · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 list 1/1 paragraph 1/1 title 2/2
Components 5
line bullet paragraph action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.